Study Of Anti-lung Cancer Effects And Mechanism Of HAS Combined With Chemotherapy

Cancer has become a common disease which threatens human health. The domestic and foreign scholars have done a large number of basic and clinical researches and have made tremendous progress. During the recent 50 years, the Department of medical oncology has taken a big step forward. Reported in the literature, highly agglutinative staphylococci (HAS)has the function of anti-tumor and immunization and adjustment. It c ould treat pleural effusion by injecting HAS, which achieves a remarkable clinical effects. This study uses HAS combined with chemotherapy drug to detect the clinical effect of the treatment of malignant pleural effusion. At the same time, this study investigates the mechanism of anti-tumor on the basic of cells and molecules for the application of anti-tumor drugs as HAS, laying the theoretical foundation and providing new experimental data.Objective: To investigate clinical effects and anti-lung cancer effects of HAS combined with chemotherapy in the treatment of malignant pleural effusion.Methods: 1. The method of clinical treatment: First all patients detain drainage tube in their chests. Within 24 hours to 48 hours they must exclude pleural effusion. Injecting into cisplatin and HAS patients NACL(0.9%,50ml),HAS(6000u), cisplatin(40mg/㎡-60mg/), dexame- thasone (10mg) and lidocaine (100mg); injecting into cisplatin group NACI (0.9%,50ml), cisplatin(40mg/㎡-60mg/㎡), dexamethasone (10mg) and lidocaine(100mg). Then clip drainage tube and ask patients to transform body position for making drugs contact with the chest well-distributed, 30 minutes once, once a week, continuous thoracic injection 2-3times.2.Experimental study: 1.The MTT method detects that HAS makes impact on proliferation of human lung cell line A549 and mouse spleen cell. 2. The Flow Cytomethy method detects that HAS makes impact on cell cycle and down-death of human lung cell line A549. 3. Reverse transcriptase polymerase chain reaction (RT-PCR)detects that HAS makes impact on apoptosis molecules of human lung adenocarci- noma cell line. 4. Reverse transcriptase polymerase chain reaction (RT-PCR) detects that HAS makes impact on immune-suppressive factor (VEGF IL-10 TGF-β) of human lung asenocarcinoma cell line A549.Results: 1. Clinical observation shows that: all 64 patents are divided into two groups, after the treatment, their pleural effusion of the patients in both groups has reduced on different levels and their clinical symptoms have improved in varying degrees. Furthermore, it has no significant adverse side effects. Comparing patients in HAS group with patients in cisplatin group, the clinical results are more obvious and the control of pleural effusion's is better. The efficiency has reached to 82.4 and comparability of two groups is remarkable. According to the score of life quality, the karnofsky of HAS is more than that in cisplatin treatment group, and the remarkable change between two groups is significant. 2. Experimental results show that: when HAS functions on human adenocarcinoma cell line A549, it could inhibit cell proliferation significantly. There are significant differences (p<0.01) and the best inhibitory concentration of HAS is 1:10. After flow cytometry has detected the human lung adenocarcinoma cell line A549, the percentage of apoptosis increases significantly. Compared with the control group, it could increase by 6.39%; after reverse transcriptase polymerase chain reaction (RT-PCR) detects human lung adenocacrcinoma A594 cells, inhibition of apoptosis expression of BCI-2mRNA reduces obviously, but the expression of pro-apoptotic molecules BaxmRNA increases clearly; leaching to the experimental results show that HAS could proliferate mouse spleen cells and thymaocyte when it is diluted into 1:10. Reverse transcription-polymerase chain reaction (RT-PCR) detects that HAS makes impact on immunosuppressive factor (VEGF,1L-10,TGF-β) of human lung asenocarcinoma A549. The result shows that after HAS functions on the A549 cell line, it could reduce expression of VEGF and FasL mRNA; but for FGF-β, mRNA expression doesn't downward obviously.Conclusion: 1. Clinical studies shows that using high- staphylococci and implanting inthe treatment of lung cancer patients with malignant pleural effusion, clinical effects are obvious---- reduction of pleural effusion in different levels, improvement of clinical symptoms in different degrees, the rising of life quality and no obvious adverse side effects. 2. Research shows that a certain concentration HAS acts on human lungAden carcinoma cell line A594 and the A594 could significantly be inhibited the proliferation. 3. Study finds that HAS can induce apoptosis in A549 cells----decreasing of adjustable suppressing apoptosis gene Bc1-2 mRNA's expression and increasing of promoting Barmen pro-apoptotic gene's expression. 4. Study shows that HAS could play a role in immune regulation through the promotion of spleen cells of the mice. 5. Study finds that HAS could adjust human Aden carcinoma cellline, A549's immunosuppressive factor mRNA's expression----HAS could significantly reduce VEGF and FASL mRNA's expression, thereby reversing the immunosuppression of tumor-mediated.